Simulations Plus, Inc. develops drug discovery and development simulation software, which is licensed to and used in the conduct of drug research for pharmaceutical companies worldwide.  The Company's other businesses are based on its proprietary software technologies and provide support for the emerging pharmaceutical enterprise.

Annual Report to Security Holders (Form ARS | Period ending 2024-12-23)

Annual Report (Form 10-K | Period ending 2024-08-31)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Simulations Plus (SLP US)

Annual Report to Security Holders (Form ARS | Period ending 2024-12-23)

Annual Report (Form 10-K | Period ending 2024-08-31)

Current Report (Form 8-K | Period ending 2024-10-23)

Current Report (Form 8-K | Period ending 2024-08-23)

Quarterly Report (Form 10-Q | Period ending 2024-05-31)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)